Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orient Pharma CoROCO:4166 +0.42%69 3-Year EBITDA Growth Rate is 107.30% as of Jun. 2026, which is 1209% above its 10-year median of 8.20. GuruFocus rates ROCO:4166 with a GF Score™ of 69/100 and a GF Value™ of NT$41.62 (Significantly Undervalued). Among 808 Drug Manufacturers companies, Orient Pharma Co ranks better than 98.02% on this metric.
During the past 12 months, Orient Pharma Co's average EBITDA Per Share Growth Rate was 46.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 107.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Orient Pharma Co was 107.30% per year. The lowest was -40.90% per year. And the median was 8.20% per year.
Orient Pharma Co (ROCO:4166) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Orient Pharma Co 3-Year EBITDA Growth Rate Related Terms
ROCO:4166 vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's 3-Year EBITDA Growth Rate falls into.
Orient Pharma Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 107.30% mean?
Orient Pharma Co (ROCO:4166) has a 3-Year EBITDA Growth Rate of 107.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Orient Pharma Co and its competitors. This is 1209% above median its historical median of 8.20. According to the industry distribution chart, Orient Pharma Co ranks #16 out of 808 companies in the Drug Manufacturers industry, placing it in the top 2%.
Is Orient Pharma Co's 3-Year EBITDA Growth Rate too high?
Orient Pharma Co's current 3-Year EBITDA Growth Rate of 107.30% is 1209% above median its 10-year median of 8.20. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Orient Pharma Co's value of 107.30% is 1105.6% above this industry median. Based on the distribution chart, Orient Pharma Co ranks #16 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orient Pharma Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #16 out of 808 companies for 3-Year EBITDA Growth Rate. This places Orient Pharma Co in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Orient Pharma Co's value of 107.30% is 1105.6% above this benchmark. While the company's 10-year median is 8.20 vs. the industry median of 8.90, Orient Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current 3-Year EBITDA Growth Rate of 107.30% is 1105.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current 3-Year EBITDA Growth Rate is 107.30%, which is 1209% above median its own 10-year median of 8.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$41.62, compared to a current price of NT$23.80 — trading 42.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 107.30%, which is 1209% above median its 10-year median of 8.20 and 1105.6% above the Drug Manufacturers industry median of 8.90. Orient Pharma Co's overall GF Score™ is 69/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current 3-Year EBITDA Growth Rate is 107.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$23.80 is trading 42.8% below its estimated GF Value™ of NT$41.62.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
3-Year EBITDA Growth Rate: 107.30% (1209% above median its 10-year median of 8.20)
GF Value™: NT$41.62 vs. price of NT$23.80 (42.8% below fair value)
Industry Position: 1105.6% above the Drug Manufacturers median (#16 of 808)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
69GF Score
Get the complete analysis for ROCO:4166
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
